Autosomal Recessive Spinocerebellar Ataxia 15 (SCAR15): Disease-Characteristics Report

Executive summary and evidence boundary

Autosomal recessive spinocerebellar ataxia 15 (SCAR15), or Salih ataxia, is an exceptionally rare, childhood-onset neurodevelopmental and slowly progressive cerebellar disorder caused by biallelic pathogenic variants in RUBCN (formerly KIAA0226). It must not be confused with autosomal-dominant SCA15, usually associated with ITPR1, or with CWF19L1-related SCAR17. The historical evidence base comprises only five patients from two Saudi families carrying the same founder frameshift; therefore, percentages below are descriptive, not robust population estimates. Open Targets maps MONDO:0014311 specifically to RUBCN and cites the foundational human studies (OpenTargets Search: autosomal recessive spinocerebellar ataxia 15).

The principal primary reports are Assoum et al., Brain, August 2010, PMID 20826435, DOI 10.1093/brain/awq181, and Seidahmed et al., BMC Neurology, 21 May 2020, PMID 32450808, DOI 10.1186/s12883-020-01761-w. The latter’s abstract states that its findings “validate the slowly progressive phenotype of Salih ataxia” and that “haplotype sharing attests to a common founder” (seidahmed2020ancientfoundermutation pages 1-3).

The following evidence matrix summarizes the central findings and their limitations.

Table: This table compiles the highest-yield disease-characteristics evidence for autosomal recessive spinocerebellar ataxia 15 (Salih ataxia), emphasizing the tiny five-patient evidence base. It separates SCAR15-specific findings from broader RUBCN biology so the strength and limits of mechanistic inference are clear.

1. Disease information

Definition

SCAR15 is a Mendelian autosomal-recessive ataxia characterized by delayed walking and speech, childhood-onset gait incoordination, dysarthria, variable limb ataxia and cognitive impairment, occasional infantile epilepsy, and mild cerebellar atrophy that may not become visible until adolescence. The original abstract described “childhood onset gait and limb ataxia, dysarthria” and limited unaided walking into the teenage years (assoum2010rundataxinanovel pages 1-2).

Identifiers and synonyms

• MONDO: MONDO:0014311.
• OMIM: 615705.
• Preferred names: autosomal recessive spinocerebellar ataxia 15; SCAR15; Salih ataxia.
• Historical terminology: KIAA0226-related recessive ataxia; rundataxin-related ataxia.
• Gene/protein: RUBCN, rubicon autophagy regulator; aliases KIAA0226, RUBICON; protein initially called rundataxin/RDTX.
• Orphanet: no confidently verified disease-specific ORPHA number was recovered.
• ICD-10/ICD-11 and MeSH: no unique SCAR15 code or heading was identified; coding generally falls under hereditary/cerebellar ataxia categories. A specific code should not be inferred.

The knowledge summarized here is principally aggregated from published family case reports, whose underlying observations are individual-patient clinical, imaging, electrophysiologic, and germline-genetic data—not EHR-derived population evidence (assoum2010rundataxinanovel pages 1-2, seidahmed2020ancientfoundermutation pages 1-3).

2. Etiology, risk, and protective factors

The necessary cause is biallelic germline RUBCN dysfunction. The demonstrated allele is a homozygous one-base deletion producing a C-terminal frameshift. The original paper reported 2927delC, p.Ala943ValfsX146; the updated transcript annotation is NM_014687:c.2624delC, p.Ala875fs. These represent transcript/numbering differences for the same founder deletion and should be normalized carefully rather than entered as independent variants (assoum2010rundataxinanovel pages 4-5, seidahmed2020ancientfoundermutation pages 3-5).

Genetic risk is greatest in relatives of a carrier and in endogamous populations in which the founder allele circulates. Both pedigrees were consanguineous; the second family’s parents were first cousins. The shared haplotype placed the mutation approximately 1,550 years, or 62 generations, in the past (seidahmed2020ancientfoundermutation pages 6-7, seidahmed2020ancientfoundermutation pages 1-3).

No susceptibility loci, modifier genes, protective alleles, environmental causes, toxins, infections, lifestyle risk factors, or validated gene–environment interactions have been reported. Consanguinity does not mechanistically cause the mutation but increases the probability that descendants inherit two copies of a rare founder allele. No diet, exposure, or behavior is known to prevent phenotypic expression in a biallelic individual.

3. Phenotypes

Across the five-patient comparison, delayed walking and delayed speech occurred in 5/5, dysarthria in 5/5, gait ataxia in 5/5, upper- and lower-limb ataxia in 4/5, cognitive impairment or low/borderline IQ in 4/5, abnormal ocular pursuit or nystagmus in 4/5, and epilepsy in 2/5. These fractions are highly unstable because the denominator is five and all patients carried one founder allele (seidahmed2020ancientfoundermutation pages 5-6, seidahmed2020ancientfoundermutation media 0e4549a2).

• Motor-developmental delay: walking occurred at 22–42 months; speech at approximately 3 to >4–5 years. Suggested HPO: Delayed gross motor development (HP:0002194) and Delayed speech and language development (HP:0000750).
• Gait and appendicular ataxia: unsteadiness generally appeared while learning to walk, at 2–3 years, although one patient’s recognized onset was 7 years. Severity ranged from examination-only signs to inability to run and limited unaided walking. Suggested HPO: Gait ataxia (HP:0002066), Limb ataxia (HP:0002070), Cerebellar ataxia (HP:0001251).
• Dysarthria: present from speech acquisition, mild to severe. Suggested HPO: Dysarthria (HP:0001260).
• Cognition: IQs in the second family were 67 and 72; two original-family patients had moderate intellectual disability without formal IQ testing, while one reportedly had no cognitive deficit. Suggested HPO: Intellectual disability (HP:0001249) or Borderline intellectual functioning (HP:0006889) where appropriate (assoum2010rundataxinanovel pages 4-5, seidahmed2020ancientfoundermutation pages 3-5).
• Epilepsy: two sisters developed seizures/infantile spasms at 7 months. One documented EEG had generalized and focal spikes, polyspikes, and slow waves. Seizures resolved with treatment. Suggested HPO: Infantile spasms (HP:0012469), Abnormal EEG (HP:0002353).
• Oculomotor signs: nystagmus or saccadic pursuit, generally in older patients. Suggested HPO: Nystagmus (HP:0000639) and Abnormality of ocular smooth pursuit (HP:0000617).
• Reflexes: lower-limb reflexes were enhanced in 3/5, diminished in 1/5, and normal in 1/5; plantar responses were flexor in all. Suggested HPO: Hyperreflexia in lower limbs (HP:0002395).
• Imaging: early MRI may be normal. One patient developed mild hemispheric/vermal atrophy with prominent folia at 18 years after normal imaging at 9 years; another had minimal superior vermian atrophy at 16 after a normal scan at 6. Suggested HPO: Cerebellar atrophy (HP:0001272) (assoum2010rundataxinanovel pages 4-5, seidahmed2020ancientfoundermutation pages 3-5).
• Neurophysiology: motor and sensory nerve conduction was normal in all five when tested, arguing against a consistent large-fiber neuropathy. BAER showed increased hearing thresholds in 2/4 tested, and VEP was abnormal in 1/4; these remain variable associated findings rather than defining features (seidahmed2020ancientfoundermutation pages 5-6, seidahmed2020ancientfoundermutation media 0e4549a2).

Quality-of-life instruments such as EQ-5D, SF-36, PROMIS, or ataxia-specific patient-reported outcomes have not been published. Nevertheless, delayed communication, impaired balance, inability to run, restricted unaided walking, special-education needs, and seizure burden plausibly affect independence, schooling, participation, and caregiver demands. This functional interpretation is supported clinically but has not been quantified with standardized QoL scales.

4. Genetic and molecular information

RUBCN is the only established causal gene. Open Targets identifies ENSG00000145016, “rubicon autophagy regulator,” as the associated target for MONDO:0014311 (OpenTargets Search: autosomal recessive spinocerebellar ataxia 15). The reported pathogenic allele is germline, homozygous, frameshifting, segregates with disease, is heterozygous in parents, was absent from 622 control chromosomes in the original work, and removes/replaces the conserved C-terminal region. The original authors considered loss of function the likely consequence (assoum2010rundataxinanovel pages 4-5).

The original screen of 172 non-Friedreich ataxia families, including nine Saudi families, detected no additional KIAA0226 mutation, emphasizing rarity. Reliable ancestry-specific gnomAD/TOPMed allele frequencies and current ClinVar classifications were not recovered and should be imported directly from those databases using the normalized HGVS expression rather than guessed (assoum2010rundataxinanovel pages 4-5).

No pathogenic missense series, dominant-negative mechanism, somatic mutation, repeat expansion, large chromosomal rearrangement, modifier gene, disease-specific methylation signature, or epigenetic mechanism has been established. CMA, karyotype, and FISH are therefore not first-line confirmation methods unless an independent chromosomal disorder is suspected.

5. Environmental information

SCAR15 is not an infectious, toxic, occupational, nutritional, radiation-associated, or lifestyle-mediated disease. There is no evidence that smoking, alcohol, exercise, diet, pollution, or pathogen exposure changes penetrance. General factors such as sedating medication, alcohol, intercurrent illness, and unsafe environments may worsen balance or falls in any ataxic person, but that is clinical prudence rather than a demonstrated SCAR15 gene–environment interaction.

6. Mechanism and pathophysiology

Disease-specific causal chain

The best-supported chain is: biallelic RUBCN frameshift → abnormal C-terminal Rubicon → failure to colocalize normally with RAB7-positive late endosomes → defective endosomal trafficking/maturation → disturbance of neuronal endolysosomal homeostasis → cerebellar circuit dysfunction and slowly developing cerebellar atrophy → gait/limb ataxia and dysarthria. The disease-specific functional follow-up concluded that truncated Rubicon lost late-endosomal RAB7 colocalization (seidahmed2020ancientfoundermutation pages 6-7, seidahmed2020ancientfoundermutation pages 5-6).

Broader RUBCN biology

Rubicon interacts with the UVRAG–BECN1–PIK3C3/VPS34 machinery. In canonical macroautophagy it generally restrains autophagosome maturation, whereas in LC3-associated phagocytosis/noncanonical autophagy it is required for PI(3)P production, NOX2-complex stabilization, and LC3 recruitment. Rubicon also participates in early-to-late endosome maturation and receptor recycling. These conclusions arise largely from cell and animal systems not carrying the human SCAR15 allele and therefore provide biological plausibility, not proof that every pathway drives the human neurologic phenotype (wong2018rubiconlc3‐associatedphagocytosis pages 9-12, wong2018rubiconlc3‐associatedphagocytosis pages 5-9).

Suggested annotations include endosomal transport (GO:0016197), late endosome to lysosome transport (GO:1902774), autophagy (GO:0006914), macroautophagy (GO:0016236), and phagocytosis (GO:0006909). Relevant cellular components include late endosome (GO:0005770), early endosome (GO:0005769), autophagosome (GO:0005776), and lysosome (GO:0005764).

No SCAR15 patient-neuron transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, CRISPR-screen, or integrated multi-omics study was identified. Claims of oxidative stress, inflammation, mitochondrial failure, or immune-mediated tissue damage should not be entered as established SCAR15 mechanisms.

7. Anatomical structures affected

The primary organ is the central nervous system, particularly the cerebellum. Imaging implicates the superior vermis and, in one patient, cerebellar hemispheres. Relevant suggestions are cerebellum (UBERON:0002037), cerebellar vermis (UBERON:0004728), and cerebellar cortex. Disease laterality is bilateral/diffuse rather than unilateral (assoum2010rundataxinanovel pages 4-5, seidahmed2020ancientfoundermutation pages 3-5).

Purkinje neurons and cerebellar granule neurons are biologically plausible vulnerable populations, but no SCAR15 neuropathology or cell-type-resolved study directly demonstrates selective loss. Suggested—not confirmed—Cell Ontology terms are Purkinje cell (CL:0000121) and cerebellar granule cell (CL:0001031). At the subcellular level, late endosomes, lysosomes, autophagosomes, and associated membrane-trafficking complexes are implicated. Peripheral nerves are not a primary demonstrated site because nerve-conduction studies were normal (seidahmed2020ancientfoundermutation pages 5-6).

8. Temporal development

Onset is pediatric and usually insidious: delayed milestones followed by unsteadiness from the acquisition of walking. The course is chronic, lifelong, and slowly progressive rather than episodic or relapsing. Ocular signs and mild MRI atrophy may emerge in the second decade. The available disability stages ranged from 0–1 in the second family to 3 in the original family; stage 3 denoted inability to run and limited walking without aid, not wheelchair dependence (seidahmed2020ancientfoundermutation pages 5-6, seidahmed2020ancientfoundermutation media 0e4549a2).

There is no validated staging system, progression-rate estimate, remission pattern, or critical therapeutic window. Seizures can remit with medication, but the underlying ataxia has not been shown to remit.

9. Inheritance and population

Inheritance is autosomal recessive. For two confirmed heterozygous parents, each pregnancy has the conventional Mendelian probabilities of 25% affected, 50% carrier, and 25% inheriting neither familial allele, assuming no unusual reproductive mechanism. Penetrance among reported homozygotes appears high, but five ascertained patients cannot establish complete penetrance. Expressivity is variable: epilepsy, cognition, reflexes, oculomotor findings, and severity differ despite the shared allele (seidahmed2020ancientfoundermutation pages 5-6).

Only two Saudi families and five historical patients were represented in the core published case literature; hence prevalence, incidence, carrier frequency, sex ratio, and global geographic distribution are unknown. Three patients were female and two male, providing no evidence for sex bias. The founder estimate and shared haplotype support enrichment in an Arab/Saudi ancestral group but do not imply ethnic exclusivity (seidahmed2020ancientfoundermutation pages 6-7, seidahmed2020ancientfoundermutation pages 1-3).

Anticipation is not expected for a frameshift disorder and has not been observed. Germline mosaicism has not been reported. Consanguinity facilitated homozygosity and discovery.

10. Diagnostics

Diagnosis requires clinical recognition plus molecular confirmation. Initial evaluation should document development, three-generation pedigree and consanguinity, cerebellar examination, eye movements, cognition, hearing/vision, seizures, and functional status. Brain MRI may be normal early and therefore cannot exclude SCAR15. EEG is indicated for suspected seizures; audiology/BAER, ophthalmologic assessment/VEP, and nerve-conduction studies are phenotype-directed. Routine CBC, electrolytes, CK, liver/renal tests, and metabolic screening were normal in the second family and are useful mainly for differential diagnosis (seidahmed2020ancientfoundermutation pages 3-5).

Genetic workflow: (1) exclude common/treatable acquired and metabolic causes; (2) use a hereditary-at­axia/neurodevelopmental panel that includes RUBCN, or WES/WGS with CNV analysis; (3) in consanguineous pedigrees, use runs of homozygosity/autozygosity; (4) confirm and segregate candidate variants by Sanger sequencing; and (5) interpret using ACMG/AMP criteria and transcript-correct HGVS. WES plus autozygome analysis diagnosed the second family (seidahmed2020ancientfoundermutation pages 3-5, seidahmed2020ancientfoundermutation pages 1-3).

WGS can detect coding, splice, CNV, and some structural variants but remains subject to interpretation limits. RNA sequencing may help resolve a suspected splice variant but is not an established SCAR15 diagnostic. CMA, karyotype, FISH, mitochondrial-DNA testing, and repeat-expansion assays do not directly test the known founder frameshift; nevertheless, repeat-expansion testing remains important in the broader ataxia differential.

Differentials include dominant ITPR1-related SCA15, CWF19L1-related SCAR17, Friedreich ataxia, ataxia with vitamin E deficiency, ataxia-telangiectasia, ARSACS, SCAN1, mitochondrial ataxias, congenital cerebellar malformations, epileptic encephalopathies, and cerebral palsy. Preserved nerve conduction, subtle late MRI change, delayed development, AR inheritance, and biallelic RUBCN variants favor SCAR15.

No newborn-screening program or biochemical biomarker exists. Once a familial variant is known, cascade carrier testing, predictive testing of at-risk siblings with appropriate counseling, prenatal diagnosis, and preimplantation genetic testing are technically feasible.

11. Outcome and prognosis

Available evidence supports slow neurologic progression with survival into at least late adolescence/young adulthood and retained walking, albeit limited in the more affected patients. No 5- or 10-year survival rate, mortality rate, life-expectancy estimate, cause-of-death pattern, or adult end-stage natural history is available. Nerve-conduction preservation and subtle MRI evolution suggest a predominantly cerebellar rather than widespread peripheral neurodegenerative course, but long-term multisystem surveillance data are absent (seidahmed2020ancientfoundermutation pages 5-6).

Morbidity includes impaired balance, falls risk, dysarthria, limited mobility, learning/intellectual disability, special-education needs, possible hearing/visual pathway abnormalities, and treatable epilepsy. Recovery of the genetic ataxia has not been documented. No molecular prognostic biomarker exists; age, baseline functional severity, cognition, epilepsy, or MRI atrophy may be clinically relevant but are unvalidated predictors.

12. Treatment

There is no approved disease-modifying, gene, cell, RNA, targeted, or immunologic therapy for SCAR15 and no RUBCN-specific interventional trial was identified. Because Rubicon inhibits canonical autophagy but supports LAP and endosomal functions, indiscriminate pharmacologic activation or inhibition of autophagy is not presently justified; pathway directionality is context-dependent (wong2018rubiconlc3‐associatedphagocytosis pages 9-12, wong2018rubiconlc3‐associatedphagocytosis pages 5-9).

Management is multidisciplinary and supportive: physical therapy for balance, coordination, strength, conditioning, and fall prevention; occupational therapy and mobility/adaptive equipment; speech-language therapy for dysarthria and swallowing assessment when indicated; developmental, educational, and neuropsychological support; audiology/vision care; and routine management of spasticity, dystonia, pain, nutrition, sleep, and mental health if they arise. Suggested NCIT concepts include Physical Therapy (NCIT:C15308), Occupational Therapy, Speech Therapy, Genetic Counseling, and Supportive Care.

In the original family, infantile spasms were treated with vigabatrin and clonazepam; the documented patient became seizure-free by age 3 and was weaned from vigabatrin by age 7. This is individual clinical evidence, not a SCAR15-specific comparative treatment trial (assoum2010rundataxinanovel pages 4-5). Riluzole, acetyl-leucine, neuromodulation, or other interventions studied in different ataxias cannot be assumed effective in SCAR15.

13. Prevention

There is no vaccine, chemoprophylaxis, lifestyle prevention, or population screening program. Primary genetic prevention consists of voluntary carrier identification and reproductive counseling in an affected family. Options include partner testing, prenatal diagnosis, preimplantation genetic testing for monogenic disease, donor gametes, or natural conception with informed risk. These must remain nondirective.

Secondary prevention comprises early molecular diagnosis, seizure recognition, developmental intervention, hearing/vision assessment, and cascade testing. Tertiary prevention includes rehabilitation, fall-proofing, mobility aids, aspiration and nutritional assessment when clinically indicated, seizure control, and prevention of contractures and deconditioning.

14. Other species and natural disease

No naturally occurring RUBCN-associated Salih-ataxia equivalent was identified in companion animals, livestock, or wildlife. The disorder is not infectious and has no zoonotic or cross-species transmission potential. RUBCN orthologs and conserved autophagy/endolysosomal functions occur broadly among vertebrates, but orthology alone does not establish natural veterinary disease.

General conditional Rubcn-deficient mouse and cellular studies demonstrate effects on autophagic flux, metabolism, bone, kidney, immunity, and neuronal protein handling; these are pathway models, not faithful natural or engineered SCAR15 models. Their phenotypes should not be imported directly into the human disease record.

15. Model organisms and research gaps

No knock-in mouse, zebrafish, Drosophila, organoid, or patient-derived iPSC model reproducing the human SCAR15 founder allele was identified. The disease-specific experimental evidence is limited principally to cellular localization/trafficking analysis of truncated Rubicon. General RUBCN-null cells and tissue-specific knockout mice are valuable for dissecting canonical autophagy, LC3-associated phagocytosis, RAB7/endosomal maturation, lipid handling, and tissue-specific consequences, but complete knockout may not model the unusual C-terminal frameshift accurately (wong2018rubiconlc3‐associatedphagocytosis pages 9-12, wong2018rubiconlc3‐associatedphagocytosis pages 5-9, seidahmed2020ancientfoundermutation pages 6-7).

Priority research needs are: ascertainment of additional ancestries and alleles; current ClinVar/gnomAD normalization of the founder deletion; international natural-history collection using SARA and patient-reported outcomes; serial quantitative MRI and digital gait measures; patient iPSC-derived Purkinje-like neurons and cerebellar organoids; knock-in models of the exact founder allele; autophagic-flux and endosomal-cargo assays in disease-relevant neurons; and transcriptomic, proteomic, and lipidomic profiling. These are prerequisites for determining whether treatment should restore Rubicon localization, correct the transcript, replace RUBCN, or modulate a specific downstream trafficking pathway.

Overall assessment

The disease–gene relationship is well supported by homozygosity, segregation, recurrence of the same allele in an unrelated family, founder-haplotype evidence, protein-domain disruption, and disease-specific localization studies. The clinical picture—early developmental delay, childhood gait/dysarthric ataxia, variable intellectual disability and epilepsy, normal nerve conduction, and subtle late cerebellar atrophy—is coherent. However, virtually every estimate of frequency, penetrance, prognosis, and treatment effect remains low-confidence because the foundational quantitative dataset contains only five patients from two related-population pedigrees (assoum2010rundataxinanovel pages 1-2, seidahmed2020ancientfoundermutation pages 1-3, seidahmed2020ancientfoundermutation media 0e4549a2).

References

1. (OpenTargets Search: autosomal recessive spinocerebellar ataxia 15): Open Targets Query (autosomal recessive spinocerebellar ataxia 15, 14 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (seidahmed2020ancientfoundermutation pages 1-3): Mohammed Z. Seidahmed, Muddathir H. Hamad, Albandary AlBakheet, Salah A. Elmalik, Abdulmajeed AlDrees, Jumanah Al-Sufayan, Ibrahim Alorainy, Ibrahim M. Ghozzi, Dilek Colak, Mustafa A. Salih, and Namik Kaya. Ancient founder mutation in rubcn: a second unrelated family confirms salih ataxia (scar15). BMC Neurology, May 2020. URL: https://doi.org/10.1186/s12883-020-01761-w, doi:10.1186/s12883-020-01761-w. This article has 20 citations and is from a peer-reviewed journal.

3. (assoum2010rundataxinanovel pages 1-2): Mirna Assoum, Mustafa A. Salih, Nathalie Drouot, Dorra H'Mida-Ben Brahim, Clotilde Lagier-Tourenne, Abdulmajeed AlDrees, Salah A. Elmalik, Taha S. Ahmed, Mohammad Z. Seidahmed, Mohammad M. Kabiraj, and Michel Koenig. Rundataxin, a novel protein with run and diacylglycerol binding domains, is mutant in a new recessive ataxia. Brain : a journal of neurology, 133 Pt 8:2439-47, Aug 2010. URL: https://doi.org/10.1093/brain/awq181, doi:10.1093/brain/awq181. This article has 59 citations.

4. (assoum2010rundataxinanovel pages 4-5): Mirna Assoum, Mustafa A. Salih, Nathalie Drouot, Dorra H'Mida-Ben Brahim, Clotilde Lagier-Tourenne, Abdulmajeed AlDrees, Salah A. Elmalik, Taha S. Ahmed, Mohammad Z. Seidahmed, Mohammad M. Kabiraj, and Michel Koenig. Rundataxin, a novel protein with run and diacylglycerol binding domains, is mutant in a new recessive ataxia. Brain : a journal of neurology, 133 Pt 8:2439-47, Aug 2010. URL: https://doi.org/10.1093/brain/awq181, doi:10.1093/brain/awq181. This article has 59 citations.

5. (seidahmed2020ancientfoundermutation pages 5-6): Mohammed Z. Seidahmed, Muddathir H. Hamad, Albandary AlBakheet, Salah A. Elmalik, Abdulmajeed AlDrees, Jumanah Al-Sufayan, Ibrahim Alorainy, Ibrahim M. Ghozzi, Dilek Colak, Mustafa A. Salih, and Namik Kaya. Ancient founder mutation in rubcn: a second unrelated family confirms salih ataxia (scar15). BMC Neurology, May 2020. URL: https://doi.org/10.1186/s12883-020-01761-w, doi:10.1186/s12883-020-01761-w. This article has 20 citations and is from a peer-reviewed journal.

6. (seidahmed2020ancientfoundermutation media 0e4549a2): Mohammed Z. Seidahmed, Muddathir H. Hamad, Albandary AlBakheet, Salah A. Elmalik, Abdulmajeed AlDrees, Jumanah Al-Sufayan, Ibrahim Alorainy, Ibrahim M. Ghozzi, Dilek Colak, Mustafa A. Salih, and Namik Kaya. Ancient founder mutation in rubcn: a second unrelated family confirms salih ataxia (scar15). BMC Neurology, May 2020. URL: https://doi.org/10.1186/s12883-020-01761-w, doi:10.1186/s12883-020-01761-w. This article has 20 citations and is from a peer-reviewed journal.

7. (seidahmed2020ancientfoundermutation pages 3-5): Mohammed Z. Seidahmed, Muddathir H. Hamad, Albandary AlBakheet, Salah A. Elmalik, Abdulmajeed AlDrees, Jumanah Al-Sufayan, Ibrahim Alorainy, Ibrahim M. Ghozzi, Dilek Colak, Mustafa A. Salih, and Namik Kaya. Ancient founder mutation in rubcn: a second unrelated family confirms salih ataxia (scar15). BMC Neurology, May 2020. URL: https://doi.org/10.1186/s12883-020-01761-w, doi:10.1186/s12883-020-01761-w. This article has 20 citations and is from a peer-reviewed journal.

8. (seidahmed2020ancientfoundermutation pages 6-7): Mohammed Z. Seidahmed, Muddathir H. Hamad, Albandary AlBakheet, Salah A. Elmalik, Abdulmajeed AlDrees, Jumanah Al-Sufayan, Ibrahim Alorainy, Ibrahim M. Ghozzi, Dilek Colak, Mustafa A. Salih, and Namik Kaya. Ancient founder mutation in rubcn: a second unrelated family confirms salih ataxia (scar15). BMC Neurology, May 2020. URL: https://doi.org/10.1186/s12883-020-01761-w, doi:10.1186/s12883-020-01761-w. This article has 20 citations and is from a peer-reviewed journal.

9. (wong2018rubiconlc3‐associatedphagocytosis pages 9-12): Sing‐Wai Wong, Payel Sil, and Jennifer Martinez. Rubicon: lc3‐associated phagocytosis and beyond. The FEBS Journal, 285:1379-1388, Apr 2018. URL: https://doi.org/10.1111/febs.14354, doi:10.1111/febs.14354. This article has 127 citations.

10. (wong2018rubiconlc3‐associatedphagocytosis pages 5-9): Sing‐Wai Wong, Payel Sil, and Jennifer Martinez. Rubicon: lc3‐associated phagocytosis and beyond. The FEBS Journal, 285:1379-1388, Apr 2018. URL: https://doi.org/10.1111/febs.14354, doi:10.1111/febs.14354. This article has 127 citations.

11. (OpenTargets Search: autosomal recessive spinocerebellar ataxia 15-CWF19L1): Open Targets Query (autosomal recessive spinocerebellar ataxia 15-CWF19L1, 0 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

Artifacts

• Edison artifact artifact-00